Agranulocytosis from Outpatient Antimicrobial Treatment with Ceftriaxone

A Case Report

Yevgeniy Genchanok, Seda S. Tolu, Heidy Wang, Shitij Arora

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Agranulocytosis from antimicrobial therapy with ceftriaxone is rare. We report a case of agranulocytosis resulting from ceftriaxone noted more than 3 weeks into therapy. CASE PRESENTATION: A 72-year-old woman who was started on ceftriaxone for septic arthritis of the left knee 3 weeks before presentation was admitted to the hospital after being found to be neutropenic on outpatient laboratory analysis. Her absolute neutrophil count on admission was 0/μL. The cause of the agranulocytosis was suspected to be ceftriaxone. The drug was stopped, and she was started on granulocyte colony-stimulating factor with gradual resolution of the neutropenia. DISCUSSION: Serious adverse effects of ceftriaxone therapy, such as agranulocytosis, must be monitored for, especially in patients who are receiving prolonged therapy or high doses. Once this cause of agranulocytosis is identified, ceftriaxone therapy should be stopped; if the patient is febrile, an infectious disease workup should be performed and antibiotics should be started; and granulocyte colony-stimulating factor should be administered with daily monitoring of the absolute neutrophil count.

Original languageEnglish (US)
JournalThe Permanente journal
Volume23
DOIs
StatePublished - Jan 1 2019

Fingerprint

Agranulocytosis
Ceftriaxone
Outpatients
Granulocyte Colony-Stimulating Factor
Neutrophils
Therapeutics
Infectious Arthritis
Neutropenia
Communicable Diseases
Knee
Fever
Anti-Bacterial Agents
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Agranulocytosis from Outpatient Antimicrobial Treatment with Ceftriaxone : A Case Report. / Genchanok, Yevgeniy; Tolu, Seda S.; Wang, Heidy; Arora, Shitij.

In: The Permanente journal, Vol. 23, 01.01.2019.

Research output: Contribution to journalArticle

@article{5f9043ac23d84e61bbf379011c87e174,
title = "Agranulocytosis from Outpatient Antimicrobial Treatment with Ceftriaxone: A Case Report",
abstract = "INTRODUCTION: Agranulocytosis from antimicrobial therapy with ceftriaxone is rare. We report a case of agranulocytosis resulting from ceftriaxone noted more than 3 weeks into therapy. CASE PRESENTATION: A 72-year-old woman who was started on ceftriaxone for septic arthritis of the left knee 3 weeks before presentation was admitted to the hospital after being found to be neutropenic on outpatient laboratory analysis. Her absolute neutrophil count on admission was 0/μL. The cause of the agranulocytosis was suspected to be ceftriaxone. The drug was stopped, and she was started on granulocyte colony-stimulating factor with gradual resolution of the neutropenia. DISCUSSION: Serious adverse effects of ceftriaxone therapy, such as agranulocytosis, must be monitored for, especially in patients who are receiving prolonged therapy or high doses. Once this cause of agranulocytosis is identified, ceftriaxone therapy should be stopped; if the patient is febrile, an infectious disease workup should be performed and antibiotics should be started; and granulocyte colony-stimulating factor should be administered with daily monitoring of the absolute neutrophil count.",
author = "Yevgeniy Genchanok and Tolu, {Seda S.} and Heidy Wang and Shitij Arora",
year = "2019",
month = "1",
day = "1",
doi = "10.7812/TPP/18-190",
language = "English (US)",
volume = "23",
journal = "The Permanente journal",
issn = "1552-5767",
publisher = "The Permanente Press",

}

TY - JOUR

T1 - Agranulocytosis from Outpatient Antimicrobial Treatment with Ceftriaxone

T2 - A Case Report

AU - Genchanok, Yevgeniy

AU - Tolu, Seda S.

AU - Wang, Heidy

AU - Arora, Shitij

PY - 2019/1/1

Y1 - 2019/1/1

N2 - INTRODUCTION: Agranulocytosis from antimicrobial therapy with ceftriaxone is rare. We report a case of agranulocytosis resulting from ceftriaxone noted more than 3 weeks into therapy. CASE PRESENTATION: A 72-year-old woman who was started on ceftriaxone for septic arthritis of the left knee 3 weeks before presentation was admitted to the hospital after being found to be neutropenic on outpatient laboratory analysis. Her absolute neutrophil count on admission was 0/μL. The cause of the agranulocytosis was suspected to be ceftriaxone. The drug was stopped, and she was started on granulocyte colony-stimulating factor with gradual resolution of the neutropenia. DISCUSSION: Serious adverse effects of ceftriaxone therapy, such as agranulocytosis, must be monitored for, especially in patients who are receiving prolonged therapy or high doses. Once this cause of agranulocytosis is identified, ceftriaxone therapy should be stopped; if the patient is febrile, an infectious disease workup should be performed and antibiotics should be started; and granulocyte colony-stimulating factor should be administered with daily monitoring of the absolute neutrophil count.

AB - INTRODUCTION: Agranulocytosis from antimicrobial therapy with ceftriaxone is rare. We report a case of agranulocytosis resulting from ceftriaxone noted more than 3 weeks into therapy. CASE PRESENTATION: A 72-year-old woman who was started on ceftriaxone for septic arthritis of the left knee 3 weeks before presentation was admitted to the hospital after being found to be neutropenic on outpatient laboratory analysis. Her absolute neutrophil count on admission was 0/μL. The cause of the agranulocytosis was suspected to be ceftriaxone. The drug was stopped, and she was started on granulocyte colony-stimulating factor with gradual resolution of the neutropenia. DISCUSSION: Serious adverse effects of ceftriaxone therapy, such as agranulocytosis, must be monitored for, especially in patients who are receiving prolonged therapy or high doses. Once this cause of agranulocytosis is identified, ceftriaxone therapy should be stopped; if the patient is febrile, an infectious disease workup should be performed and antibiotics should be started; and granulocyte colony-stimulating factor should be administered with daily monitoring of the absolute neutrophil count.

UR - http://www.scopus.com/inward/record.url?scp=85070066599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070066599&partnerID=8YFLogxK

U2 - 10.7812/TPP/18-190

DO - 10.7812/TPP/18-190

M3 - Article

VL - 23

JO - The Permanente journal

JF - The Permanente journal

SN - 1552-5767

ER -